No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LH240517C210000
- 2.67
- +1.02+61.82%
15min DelayTrading May 15 12:27 ET
2.85High1.90Low
2.45Open1.65Pre Close34 Volume735 Open Interest210.00Strike Price7.83KTurnover19.95%IV0.20%PremiumMay 17, 2024Expiry Date2.53Intrinsic Value100Multiplier2DDays to Expiry0.15Time Value100Contract SizeAmericanOptions Type0.7935Delta0.0823Gamma72.04Leverage Ratio-0.2339Theta0.0111Rho57.17Eff Leverage0.0496Vega
Intraday
- 5D
- 1D
News
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy
Labcorp is now the only lab that can detect preeclampsia risk across all pregnancy trimesters BURLINGTON, N.C., May 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comp
Form 144 | Laboratory Corp of America(LH.US) Officer Proposes to Sell 421.66K in Common Stocks
SEC FILLINGS DISCLOSED/ May 14, $Laboratory Corp of America(LH.US)$ Officer van der Vaart Sandra D intends to sell 2,000 shares of its common stock on May 14, with a total market value of approximatel
Express News | NYSE Order Imbalance 59063.0 Shares on Sell Side
We Think Shareholders May Want To Consider A Review Of Laboratory Corporation of America Holdings' (NYSE:LH) CEO Compensation Package
Labcorp to Webcast Its Annual Meeting of Shareholders
BURLINGTON, N.C., May 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be
Laboratory: Invitae Acquisition Advances Labcorp's Specialty Testing Strategy in Key Areas Such as Oncology and Rare Diseases >LH
Laboratory: Invitae Acquisition Advances Labcorp's Specialty Testing Strategy in Key Areas Such as Oncology and Rare Diseases >LH
Comments
The company's stock seems overpriced compared to its peers, suggesting limited potential for further growth. Its low beta indicates it may not align with industry levels soon.
Insider selling shares below current price suggests contentment with lower valuation. Lack of insider buying and low insider ownership make the company a cautious investment choice.
Investors' optimism about Laboratory Corporation's performance could lead to inflated stock prices. The high share price puts existing and new shareholders at potential risk, possibly paying an unnecessary premium.
Labcorp's acquisition set to fortify its Massachusetts presence and push its goal of broadening cost-effective lab testing. The partnership with Baystate Health aims at promoting efficient, advanced healthcare services and improving patient and provider experience.
Read more